Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As User Fee Date Nears, Australia’s QRxPharma Moves To POC For MoxDuo CR Formulation; Secures Actavis As Partner

This article was originally published in PharmAsia News

Executive Summary

The company looks to position its dual-opioid combination against Purdue Pharma’s OxyContin.

You may also be interested in...

Australia's QRxPharma Files NDA With U.S. FDA For Combo Opioid That Looks Safer Than Single Compounds

Sydney-headquartered QRxPharma filed in late July its MoxDuo IR (morphine/oxycodone) NDA with U.S. FDA for the treatment of moderate to severe acute pain. The NDA was submitted under the 505(b)(2) pathway, which allows for historical data because the two components of the dual opioid are already approved. Interestingly, the morphine and oxycodone combo appears to be safer than the two single compounds

Aspen's Acquisition of Sigma For APAC Expansion Comes At Time Of Generics Uncertainty In Australia

TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division

QRxPharma Makes Pain Connection By Teaching Old Drugs New Tricks

PERTH, Australia - Sydney-headquartered QRxPharma formed a development deal with China Aoxing Pharmaceutical for QRxPharma's lead candidate MoxDuo IV, an intravenous formulation of morphine and oxycodone for treating moderate to severe pain


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts